Sensitive radioimmunoassay (RIA) procedures are commercially available for the detection of hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg), and antibody to HBeAg (antiHBe), each of which is associated with hepatitis B virus (HBV) infection. In most patients convalescing from acute hepatitis B, there is a period of several weeks to several months between the disappearance of HBsAg and the appearance of anti-HBs, when anti-HBc is the only detectable serological marker other than anti-HBe, which may or may not be present. Anti-HBc, alone or together with anti-HBe, may also be observed in some individuals who have recovered from a past HBV infection, with the subsequent loss of detectable anti-HBs. Since a patient with detectable anti-HBc in the absence of HBsAg and anti-HBs is potentially infectious during convalescence (5) , it is important to determine whether this serological pattern is due to recent or past HBV infection. Several studies have shown that immunoglobulin M (IgM) antiHBc is almost always present at the onset of acute hepatitis B and persists for several months to more than 2 years, depending on the sensitivity of the assay (4, (10) (11) (12) . The 5 months. Ten serial serum specimens were also collected 7 to 234 days after the onset of clinical hepatitis from one hepatitis B case with HBsAg persisting in the serum for more than 7 months. The 135 serial serum specimens from these 21 patients were tested for the presence of IgM anti-HBc as well as HBsAg, non-class-specific anti-HBc, anti-HBs, HBeAg, and anti-HBe. Convalescent-phase serum specimens were available from three of four cases classified as hepatitis A and were tested for the presence of IgM anti-HAV.
Tests for HBsAg, anti-HBc, anti-HBs, HBeAg, anti-HBe, and anti-HAV. Sera were tested by RIA for the presence of HBsAg (AUSRIA II, Abbott Laboratories, North Chicago, Ill.), anti-HBc (CORAB, Abbott Laboratories), anti-HBs (AUSAB, Abbott Laboratories), HBeAg and anti-HBe (Abbott Laboratories), and anti-HAV (HAVAB, Abbott Laboratories).
Tests for IgM anti-HBc and IgM anti-HAV. IgM was separated from IgG by reorienting sucrose gradient high-speed centrifugation using an SV-288 vertical rotor (DuPont Instruments, Newton, Conn.) and an RC-5B superspeed centrifuge with automatic rate controller (DuPont Instruments). A 0.25-ml amount of anti-HBc or anti-HAV positive serum was diluted in 0.75 ml of phosphate-buffered saline (pH 7.2), layered on top of a 34-ml linear 5 to 20% (wt/wt) sucrose gradient, and covered with a 1-ml mineral oil overlay. The 5 and 20% gradient solutions were prepared with sucrose for density gradient centrifugation (Beckman Instruments, Inc., Palo Alto, Calif.) dissolved in phosphate-buffered saline. The gradient solutions were mixed in a custom-made gradient former with two interconnected 14-by-110-mm cylindrical chambers. A 17-ml volume of 5% sucrose was placed in the mixing chamber, and 17 ml of 20% sucrose was placed in the reservoir so that the light solutions poured into the 25-by-98-mm polyallomer centrifuge tube (DuPont Instruments) first, through a piece of tubing reaching to the bottom of the tube. Up to eight gradients were centrifuged at a time for 15 h at 20,000 rpm and 5°C with the setting on slow cycle and the automatic rate controller dial on 45. The tubes were bottom-punctured after centrifugation, and 11 Figure 3 shows the persistence of IgM anti-HBc after the onset of symptoms in relation to the other HBV-associated serological markers in 20 of the 31 cases classified as acute hepatitis B (Table 1 ). All 20 patients had detectable HBsAg and non-class-specific anti-HBc within 1 week after onset of disease. HBsAg remained detectable in all patients tested for at least 4 weeks and became undetectable within 17 weeks in all but two patients, where it persisted for up to 19 weeks. Non-class-specific anti-HBc remained detectable during acute illness, convalescence, and recovery in every case. All 20 patients had IgM anti-HBc within 1 week after onset, and this marker was present for at least 7 weeks in each patient tested. The incidence of IgM anti-HBc positivity declined from 94% at 8 weeks to 33% at 12 weeks after onset. Only 25% remained IgM anti-HBc positive by 13 weeks, and this marker was not detected beyond 17 weeks. IgM anti-HBc persisted for a period equal to or greater than that for HBsAg in 58% of patients. HBeAg was present in ail patients tested within 2 weeks after onset. The incidence of HBeAg positivity declined from 73% at 3 weeks to 40% at 4 weeks after onset. Only 20% remained HBeAg positive by 6 weeks, and this marker was not detected beyond 8 weeks. IgM anti-HBc remained detectable for as long as or longer than HBeAg in ail 20 patients. In 13 of 20 (65%) patients, there was a period of several weeks to several months between the disappearance of HBsAg and the appearance of anti-HBs, when anti-HBc was the only detectable serological marker other than anti-HBe, which was present in all 13 . IgM anti-HBc persisted for several weeks beyond the disappearance of HBsAg in 6 of these 13 patients (46%).
In addition to the 20 patients shown in Fig. 3 (10, 11) . This procedure requires exact quantitation of IgM anti-HBc to distinguish between either recent and past acute hepatitis B, or transient and chronic HBV infections. A previous study (12) described a sucrose gradient ultracentrifugation technique for the detection of IgM anti-HBc which also employed the CORAB RIA procedure for detection of anti-HBc in IgM-containing serum fractions, where IgM anti-HBc persisted for up to 15 months. The shorter period of IgM anti-HBc positivity observed in the present report is almost certainly due to the initial 1:4 dilution of serum as weil as to differences in the sucrose gradient centrifugation technique used. This study (Fig. 3 ) and a previous report (4) (8, 13, 16) or enzyme immunoassay (6, 7, 14, 16) procedures are used for the detection of IgM anti-HAV, dilution of sera or titration of IgM anti-HAV is necessary for diagnosis of recent infection since low titers of this antibody may be present long after the acute illness. The sensitivity of the HAVAB-M RIA procedure (Abbott Laboratories), which has recently become commercially available for the detection of specific IgM antibody against HAV, has been adjusted to detect levels of IgM anti-HAV only in the first 4 to 6 months after onset of illness. This is accomplished by first diluting patient sera more than 1:4,000, permitting a diagnosis to be made after testing only one serum sample. In this study, we were able to demonstrate IgM anti-HAV in four patients at the onset of acute hepatitis A which became undetectable within 3 to 4 months in three patients with postrecovery serum available. IgM anti-HAV was also absent in 10 acute hepatitis B and NANB hepatitis patients with detectable non-class-specific anti-HAV. Therefore, the sensitivity of the assay for IgM anti-HAV described in this study is similar to that reported by others (2, 9) and appears to be appropriate for diagnosis of recent HAV infection without requiring additional serum dilution or IgM anti-HAV titration.
